Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

M&T Bank Corp cut its position in GSK plc (NYSE:GSK – Free Report) by 10.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...

We recently compiled a list of the 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where GSK ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...